Oncology and Hematology

Episodes 49-64 of 94

• 

  RestartResume

  Let’s Discuss Transplantation

  RestartResume

  Let’s Discuss Transplantation

  MinuteCE®

  Let’s Discuss Transplantation

  1.00 program credit

  • 

    

    Biree Andemariam, MD

  1.00 program credit

• 

  RestartResume

  Making the Transition: Managing Patients with Sickle Cell Disease Across the Lifespan

  RestartResume

  Making the Transition: Managing Patients with Sickle Cell Disease Across the Lifespan

  MinuteCE®

  Making the Transition: Managing Patients with Sickle Cell Disease Across the Lifespan

  1.00 program credit

  • 

    

    Biree Andemariam, MD

  1.00 program credit

• 

  RestartResume

  Implementing the Sickle Cell Treatment Regimen

  RestartResume

  Implementing the Sickle Cell Treatment Regimen

  MinuteCE®

  Implementing the Sickle Cell Treatment Regimen

  1.00 program credit

  • 

    

    Biree Andemariam, MD

  • 

    

    Caroline Freiermuth, MD

  1.00 program credit

• 

  RestartResume

  A Quick Look at Standard Treatments for Sickle Cell Disease

  RestartResume

  A Quick Look at Standard Treatments for Sickle Cell Disease

  MinuteCE®

  A Quick Look at Standard Treatments for Sickle Cell Disease

  1.00 program credit

  • 

    

    Biree Andemariam, MD

  • 

    

    Caroline Freiermuth, MD

  1.00 program credit

• 

  MinuteCE®

  Sickle Cell Disease Across the Life Span: What Your Patients Want You to Know

  1.00 credit 10 episodes

  • 

    

    Biree Andemariam, MD

  • 

    

    Caroline Freiermuth, MD

  1.00 credit 10 episodes

• 

  RestartResume

  The Burden of Sickle Cell Disease for Patients and Their Families

  RestartResume

  The Burden of Sickle Cell Disease for Patients and Their Families

  MinuteCE®

  The Burden of Sickle Cell Disease for Patients and Their Families

  1.00 program credit

  • 

    

    Biree Andemariam, MD

  1.00 program credit

• 

  RestartResume

  Preventative Management of Sickle Cell Disease Complications

  RestartResume

  Preventative Management of Sickle Cell Disease Complications

  MinuteCE®

  Preventative Management of Sickle Cell Disease Complications

  1.00 program credit

  • 

    

    Biree Andemariam, MD

  • 

    

    Caroline Freiermuth, MD

  1.00 program credit

• 

  RestartResume

  Diverse Manifestations of Sickle Cell Disease

  RestartResume

  Diverse Manifestations of Sickle Cell Disease

  MinuteCE®

  Diverse Manifestations of Sickle Cell Disease

  1.00 program credit

  • 

    

    Biree Andemariam, MD

  • 

    

    Caroline Freiermuth, MD

  1.00 program credit

• 

  RestartResume

  Why Do We Need New Therapies for Sickle Cell Disease?

  RestartResume

  Why Do We Need New Therapies for Sickle Cell Disease?

  MinuteCE®

  Why Do We Need New Therapies for Sickle Cell Disease?

  1.00 program credit

  • 

    

    Biree Andemariam, MD

  • 

    

    Caroline Freiermuth, MD

  1.00 program credit

• 

  RestartResume

  Keeping Pace in Hematologic Malignancies: 2023
  Contextualizing the Evidence: Newly Diagnosed AML in Difficult-to-Treat Subtypes

  RestartResume

  Keeping Pace in Hematologic Malignancies: 2023
  Contextualizing the Evidence: Newly Diagnosed AML in Difficult-to-Treat Subtypes

  CME/CE

  Keeping Pace in Hematologic Malignancies: 2023
  Contextualizing the Evidence: Newly Diagnosed AML in Difficult-to-Treat Subtypes

  0.50 credits

  • 

    

    Harry Paul Erba, MD, PhD

  • 

    

    Courtney DiNardo, MD

  0.50 credits

• 

  RestartResume

  Delivering Change: Mechanisms to Address Racial Healthcare Disparities in Multiple Myeloma

  RestartResume

  Delivering Change: Mechanisms to Address Racial Healthcare Disparities in Multiple Myeloma

  CME/CE

  Delivering Change: Mechanisms to Address Racial Healthcare Disparities in Multiple Myeloma

  0.25 credits

  • 

    

    Joseph Mikhael, MD

  • 

    

    Monique Hartley-Brown, MD

  • 

    

    Brandon Blue, MD

  0.25 credits

• 

  RestartResume

  In the Medical Spotlight: Antibody-Drug Conjugates in Advanced HER2-Positive Gastric/Gastroesophageal Junction Cancer

  RestartResume

  In the Medical Spotlight: Antibody-Drug Conjugates in Advanced HER2-Positive Gastric/Gastroesophageal Junction Cancer

  CME/CE

  In the Medical Spotlight: Antibody-Drug Conjugates in Advanced HER2-Positive Gastric/Gastroesophageal Junction Cancer

  0.25 credits

  • 

    

    John L. Marshall, MD

  0.25 credits

• 

  RestartResume

  Antibody-Drug Conjugates in FL

  RestartResume

  Antibody-Drug Conjugates in FL

  MinuteCE®

  Antibody-Drug Conjugates in FL

  1.00 program credit

  • 

    

    Matthew J. Matasar, MD

  • 

    

    Kami Maddocks, MD

  1.00 program credit

• 

  RestartResume

  First-Line Treatment of Adults with Classical Hodgkin Lymphoma 

  RestartResume

  First-Line Treatment of Adults with Classical Hodgkin Lymphoma 

  MinuteCE®

  First-Line Treatment of Adults with Classical Hodgkin Lymphoma 

  1.00 program credit

  • 

    

    Alex Herrera, MD

  • 

    

    Alison J. Moskowitz, MD

  1.00 program credit

• 

  RestartResume

  Clinical Implications of Bispecific Antibodies and Antibody-Drug Conjugates in FL

  RestartResume

  Clinical Implications of Bispecific Antibodies and Antibody-Drug Conjugates in FL

  MinuteCE®

  Clinical Implications of Bispecific Antibodies and Antibody-Drug Conjugates in FL

  1.00 program credit

  • 

    

    Kami Maddocks, MD

  • 

    

    Matthew J. Matasar, MD

  1.00 program credit

• 

  RestartResume

  Bispecific Antibodies in FL

  RestartResume

  Bispecific Antibodies in FL

  MinuteCE®

  Bispecific Antibodies in FL

  1.00 program credit

  • 

    

    Kami Maddocks, MD

  • 

    

    Matthew J. Matasar, MD

  1.00 program credit

• Previous
• 1
• 2
• 3
• 4
• 5
• 6
• Next